Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

114.21USD
16 Nov 2018
Change (% chg)

$2.33 (+2.08%)
Prev Close
$111.88
Open
$111.83
Day's High
$115.27
Day's Low
$111.00
Volume
137,345
Avg. Vol
133,124
52-wk High
$195.97
52-wk Low
$83.56

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: 2.79
Market Cap(Mil.): $5,112.11
Shares Outstanding(Mil.): 46.89
Dividend: --
Yield (%): --

Financials

  SAGE.OQ Industry Sector
P/E (TTM): -- 79.36 29.34
EPS (TTM): -6.40 -- --
ROI: -47.57 -0.30 13.58
ROE: -47.77 -2.98 15.11

FDA panel recommends Sage's postpartum depression treatment

An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

Nov 02 2018

UPDATE 2-FDA panel recommends Sage's postpartum depression treatment

Nov 2 An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

Nov 02 2018

Sage's postpartum depression treatment benefits outweigh risk: FDA panel

Nov 2 The benefits of Sage Therapeutics Inc's experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said on Friday.

Nov 02 2018

Earnings vs. Estimates